Cumulative incidence of breast induration
Fig. 1 · Panel Induration_grade_2-3
Panel Induration_grade_2-3 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kristine Wiborg Høgsbjerg, Else Maae, Mette Holck Nielsen, Marie Louise Holm Milo, Maja Vestmø Maraldo, Peer Michael Christiansen, Mette Skovhus Thomsen, Jens Overgaard, Birgitte Vrou Offersen, Danish Breast Cancer Group Radiotherapy Committee
Breast 84 104587
PURPOSE: Following breast-conserving surgery (BCS), patients with narrow surgical margins frequently undergo repeat surgery (RS) or receive a tumour-bed boost to reduce the risk of local recurrence. Both interventions may increase the risk of late toxicity, including breast induration and adverse cosmetic outcomes. Comparative long-term data on these outcomes remain limited. This post hoc analysis assessed the impact of RS and tumour-bed boost on grade 2-3 breast induration and cosmetic outcomes in patients receiving whole-breast irradiation (WBI) for early-stage breast cancer or ductal carcinoma in situ (DCIS). RESULTS: The analysis included 1919 patients from two multicentre randomised phase III trials within the Danish Breast Cancer Group (DBCG): DBCG HYPO (WBI 50Gy/25fr versus 40Gy/15fr) and DBCG PBI (40Gy/15fr, WBI versus partial breast irradiation (PBI)). Of these, 303 patients (16 %) underwent RS and 220 patients (11 %) received a boost. Patients were categorised into four groups: 'RS and boost', 'boost only', 'RS only', and 'No RS, no boost'. At 5 years, the cumulative incidence of grade 2-3 breast induration was highest in the 'RS and boost' group (30.7 %), followed by 'boost only' (25.7 %), 'RS only' (18.1 %), and 'No RS, no boost' (13.5 %). Adjusted hazard ratios confirmed this pattern. No significant differences in cosmetic outcomes were observed between the 'RS only' and 'boost only' groups at 3 or 5 years. CONCLUSIONS: A tumour-bed boost was associated with a higher risk of breast induration compared to RS, with no difference in cosmetic outcome.
2 个 Figure · 2 个 KM 面板
Fig. 1 Cumulative incidence of breast induration: Repeat surgery yes/no. The cumulative incidence of grade 2–3 breast induration at 3 and 5 years, estimated at 3.5 and 5.5 years, respectively. RS, repeat surgery. NoRS, no repeat surgery. HR, hazard ratio; Unadj., unadjusted; adj. HR was adjusted for age, smoking status, irradiated volume (V95 %), endocrine therapy, and dose/fractionation.
Fig. 1 · Panel Induration_grade_2-3
Panel Induration_grade_2-3 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 Cumulative incidence of breast induration: Repeat surgery vs. boost. The cumulative incidence of grade 2–3 breast induration at 3 and 5 years, estimated at 3.5 and 5.5 years, respectively. RS, repeat surgery. B, boost.
Fig. 2 · Panel Induration_grade_2-3
Panel Induration_grade_2-3 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。